Fibrinolytic Therapy with Streptokinase for Established Experimental Glomerulonephritis

Publisher Website
Google Scholar
Abstract
The efficacy of fibrinolytic therapy with streptokinase was assessed in rabbits developing anti-glomeru-lar basement membrane antibody induced glomerulonephritis. Untreated animals developed renal failure (mean creatinine 615 ± 120 μM/l) and a severe glomerulonephritis with prominent fibrin deposition. Streptokinase treatment of animals with established disease (creatinine 204 ± 35 μM/l) reduced renal impairment (creatinine 256 ± 68 μM/1, p < 0.025) and fibrin deposition. Treatment of more advanced disease (creatinine 416 ± 68 μM/l) did not preserve renal function (creatinine, 518 ± 106 μM/l), although glomerular fibrin deposition was reduced. These studies indicate that fibrinolytic therapy with streptokinase reduces glomerular fibrin deposition and, if used early, protects from loss of renal function.